{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-002563","form_type":"8-K","ticker":"KLRS","cik":"0001754068","company_name":"Kalaris Therapeutics, Inc.","filed_at":"2024-01-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.401610+00:00","generated_at":"2026-06-07T04:07:06.417486+00:00","sec_items":["2.05"],"event_type":"other_material","sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"AlloVir reduces workforce by ~95%; expects $13M in severance charges","bullets":["Board approved cutting ~95% of employees to preserve capital after discontinuing three global Phase 3 posoleucel studies (announced Dec 22, 2023).","Reduction primarily in Q1 2024, substantially complete by April 15, 2024.","Expects ~$13M in personnel-related restructuring charges (severance and benefits) largely incurred in Q1 2024.","Additional charges may arise from retention efforts or other events."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-002563","json":"https://secwatch.observer/filing/0001193125-24-002563.json","markdown":"https://secwatch.observer/filing/0001193125-24-002563.md","text":"https://secwatch.observer/filing/0001193125-24-002563.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1754068/000119312524002563/0001193125-24-002563-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1754068/000119312524002563/d35101d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T04:07:06.417486+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0f5b2e9db399a6323ff9f02b2d3eb06fb5f410d8","claim":"Kalaris Therapeutics, Inc. announced a restructuring with charges of approximately $13 million (approximately 95% of AlloVir’s current employee base).","evidence_excerpt":"2024 and expects to be substantially completed by April 15, 2024. As a result of these actions, AlloVir expects to incur personnel-related restructuring charges of approximately $13 million in connection with one-time employee termination cash expenditures, including severance and other benefits, which are expected to be substantially incurred in the first quarter","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1754068/000119312524002563/0001193125-24-002563-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $13 million"},{"label":"Headcount","value":"approximately 95% of AlloVir’s current employee base"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}